Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells

Biochem J. 2003 Oct 15;375(Pt 2):395-403. doi: 10.1042/BJ20030556.

Abstract

Cyclic ADP-ribose (cADPR), a universal calcium mobilizer from intracellular stores, was recently demonstrated to stimulate proliferation of various cell types. The role of cADPR in a specific process of monocyte- and plasma-mediated activation of T-lymphocytes by lipopolysaccharide (LPS) was addressed using human mononuclear cells from peripheral blood (PBMCs). Incubation of PBMCs with 0.1 microg/ml of LPS for 24 h provided a doubling in the intracellular levels of cADPR as compared with unstimulated PBMCs. The cADPR increase was abolished either by prior removal of monocytes or by pre-incubating a whole PBMC population with a monoclonal antibody against the monocyte marker CD14. The increased concentrations of intracellular cADPR elicited by LPS stimulation were paralleled by significant increases in NAD+ levels and in the activities of ectocellular and membrane-bound fractions of ADP-ribosyl cyclase/cADPR hydrolase activities. A cytosolic ADP-ribosyl cyclase was also detectable in PBMCs and its activity was comparably enhanced by LPS stimulation. This soluble cyclase is distinguished from the membrane-bound cyclase by both substrate and inhibitor sensitivities. LPS-stimulated PBMCs showed 2-3-fold increases of intracellular calcium ([Ca2+]i), and these changes were prevented completely by the cADPR antagonist 8-Br-cADPR and by ryanodine. Both compounds, and the cyclase inhibitor nicotinamide, significantly inhibited the T-lymphocyte proliferation induced by LPS in PBMCs. These results demonstrate that cADPR plays a role of second messenger in the adaptive immune recognition process of LPS-stimulated proliferation of PBMCs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • ADP-ribosyl Cyclase / metabolism
  • Antibodies, Monoclonal / pharmacology
  • Calcium / metabolism
  • Cell Division / drug effects
  • Cyclic ADP-Ribose / analogs & derivatives
  • Cyclic ADP-Ribose / antagonists & inhibitors
  • Cyclic ADP-Ribose / metabolism*
  • Dose-Response Relationship, Drug
  • Humans
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / metabolism
  • Lipopolysaccharide Receptors / immunology
  • Lipopolysaccharides / pharmacology*
  • Monocytes / physiology
  • N-Glycosyl Hydrolases / metabolism
  • NAD / metabolism
  • Ryanodine / pharmacology
  • Second Messenger Systems / physiology*
  • Thapsigargin / pharmacology
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Lipopolysaccharide Receptors
  • Lipopolysaccharides
  • NAD
  • Cyclic ADP-Ribose
  • Ryanodine
  • Thapsigargin
  • GDP-ribosyl cyclase
  • N-Glycosyl Hydrolases
  • ADP-ribosyl Cyclase
  • Calcium